Big Pharma is all heart. Here is a striking example of its deep concern for our collective and individual well being: In New Delhi, 49 babies died in clinical trials in just 30 months. That’s one baby every 0.61 months, a little over half.
Did no one notice? Did no one want to give up the payments they were getting? How much as the premier All India Institute of Medicine getting per baby? Who was getting it?
How many of the responsible people will go to jail?
What do you learn in this type of trial from a baby? Or are they simply the most vulnerable and helpless group so they make great experimental subjects.
I have a lot more questions, and I bet you do, too.
But the answers that are clear are pretty grim. I am reminded of the Polish vagrants, more than 300 of them, who for $1 or $2 were injected with the Sanofi-Pasteur vaccine. That dollar cost many of them their lives and the doctors and nurses involved are on trial for murder (as is a sister company, Sanofi Aventis, for homicide because of the contaminated Hepatitis B Vaccine they were given.
The stories go on and on and on of Big Pharma and the Illness Care industry using us as their guinea pigs wth no regard for us and our well-being.
Be warned. The next time you hear that a vaccine or a pharmaceutical is good for you, ask if the pronoun is correct or if what you are really being told is “the Vaccine or pharmaceutical is good for ME, the doctor or the hospital or the Drug company.”
Yours in health and freedom,
Rima E. Laibow, MD
Natural Solutions Foundation
49 babies died during clinical trials at AIIMS
Sunday, August 17, 2008
New Delhi: As many as 49 babies have died during clinical trials at the premier All India Institute of Medical Sciences (AIIMS) during the last two-and-a-half years, the reply to a Right to Information (RTI) query has revealed.
The AIIMS paediatrics department conducted 42 sets of trials on 4,142 babies – 2,728 of them below the age of one – since Jan 1, 2006.
Forty-nine babies died during the trials. AIIMS says the deaths amounted to a 1.18 percent mortality rate, according to its reply to the RTI query.
“A total of 49 deaths corresponding to 1.18 percent mortality among the enrolled patients were recorded in the studies. These include deaths both in the control and intervention groups, as per the designs of individual studies,” the reply says.
The reasons for the babies’ deaths, their ages or their gender are not contained in the reply – since these were not specifically asked by the applicant, Rahul Verma, founder of NGO Uday Foundation for Congenital Defects and Rare Blood Groups.
Verma, in fact, had filed separate queries with the same set of questions with the paediatrics department and the paediatrics surgery department. He says he received an unsatisfactory reply from the latter and is going to file an appeal in the case.
Clinical trials are research studies that test how well new medical formulations work on people. Each study attempts to find better ways to prevent, screen for, diagnose, and treat a disease.
If carefully conducted, clinical trials are the safest and fastest way of finding treatments that work.
In reply to a query on who the five top funding agencies for the trials were, AIIMS named the institute itself, the Indian Council of Medical Research (ICMR), the Department of Biotechnology (DBT), the World Health Organisation (WHO) and the Johns Hopkins Bloomberg School of Public Health in the US.
Five foreign-manufactured medicines were tested during the trials. They were:
* Zinc tablets for treating Zinc deficiency and serving as a nutritional supplement,
* Olmesartan and Valsartan for treating blood pressure related problems,
* Rituximab for treating chronic focal encephalitis, a condition affecting the brain, and
* Gene-activated human glucocerebrosidase – for treating Gaucher disease that affects the liver.
In reply to another query, AIIMS said that before conducting the trials, it had taken clearance from its own Ethics Committee, the Health Ministry Steering Committee (HMSC) on ethics and the National Ethics Committees of ICMR and DBT.
Verma, however, maintained that there were legal and ethical lacunae in the system as permissions had to be sought from different agencies depending on the nature of the trials.